Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + MASCT
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules
- Administration
- Oral, Intravenous, Intradermal
01
Overview
Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively targets and inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), thereby blocking tumor angiogenesis. MASCT (Multiple Antigens Specific Cellular Therapy) is a personalized cellular immunotherapy involving dendritic cells loaded with multiple tumor-associated antigens and activated cytotoxic T lymphocytes. The combination of apatinib and MASCT is being investigated for its potential synergistic effects in treating advanced solid tumors, where apatinib may normalize tumor vasculature and enhance the infiltration and activity of the MASCT-derived immune cells. This specific regimen was evaluated in a Phase I/IIa study at The First People's Hospital of Lianyungang.
- Brand names
- Aitan
- Other names
- RivoceranibMultiple Antigens Specific Cellular Therapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)SRC (Proto-oncogene tyrosine-protein kinase Src)
Beyond the preview
Go deeper on apatinib + MASCT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + MASCT.